Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2.

Cancer research

O'Leary PC, Chen H, Doruk YU, Williamson T, Polacco B, McNeal AS, Shenoy T, Kale N, Carnevale J, Stevenson E, Quigley DA, Chou J, Feng FY, Swaney DL, Krogan NJ, Kim M, Diolaiti ME, Ashworth A. Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2. Cancer Res. 2022 11 02; 82(21):3950-3961.

2022

https://researcherprofiles.org/profile/339670815

36273492

O'Leary PC, Chen H, Doruk YU, Williamson T, Polacco B, McNeal AS, Shenoy T, Kale N, Carnevale J, Stevenson E, Quigley DA, Chou J, Feng FY, Swaney DL, Krogan NJ, Kim M, Diolaiti ME, Ashworth A

Contact CTSI

CTSI Identity

Accelerating Research to Improve Health

The UCSF Clinical and Translational Science Institute (CTSI) is part of the Clinical and Translational Science Award (CTSA) program funded by the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) (Grant Number UL1 TR001872). The content of this website is solely the responsibility of CTSI and does not necessarily represent the official views of the NIH.

Cite CTSI NIH Funding Acknowledgment: Important — All publications resulting from the utilization of CTSI resources are required to credit the CTSI grant by including the NIH Funding acknowledgment and must comply with NIH Public Access Policy.

Search form

You are here

Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2.